![Progression-free survival following primary staging with [¹⁸F]PSMA-1007 PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA PET randomized controlled trial episode artwork](https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/16079020/16079020-1630667307527-f22dc9ee28cb5.jpg)
EPISODE · Apr 7, 2026 · 5 MIN
Progression-free survival following primary staging with [¹⁸F]PSMA-1007 PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA PET randomized controlled trial
from Medical Digest & Congress Report · host Medical Congress News
Karen Middelbo Buch-Olsen and Mads Hvid Poulsen present the highly anticipated results from the PRISMA PET randomized controlled trial, comparing progression-free survival in prostate cancer staging between [¹⁸F]PSMA-1007 PET/ceCT and Na[¹⁸F]F-PET/ceCT at the EAU 2026 Annual Congress.Video: https://medicaldigest.org/scientific-contents/interview:progression-free-survival-following-primary-staging-fpsma-1007-petcect-versus-naff-petcect-prostate-cancer-results-prisma-pet-randomized-controlled-trial
Embed this episode
Ready to play
Progression-free survival following primary staging with [¹⁸F]PSMA-1007 PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA PET randomized controlled trial
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.